Asset Details
Do you wish to reserve the book?
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies
Do you wish to request the book?
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies
2024
Overview
INTRODUCTION Little is known regarding the relationship between anticholinergic medications and frailty in dementia with Lewy bodies (DLB). METHODS Anticholinergic Cognitive Burden Scale (ACB) and Claims‐based Frailty Index scores were calculated for 12 months prior to the dementia diagnosis using electronic medical record and claims data. Logistic regression was used to estimate the association between ACB and odds of frailty. RESULTS Compared to controls (n = 525), a diagnosis of DLB (n = 175; adjusted odds ratio [aOR]: 15.1, 95% confidence interval [CI]: 7.0–33.9) or Alzheimer's disease (AD: n = 525; aOR = 7.7, 95% CI: 4.4–13.7) was associated with an increased odds of frailty. Patients with DLB had greater prescriptions for anticholinergic medications than patients with AD (pB < 0.001; 23% vs 9.7%). ACB was positively correlated with frailty for all groups (r = 0.30 to 0.47, p < 0.001). DISCUSSION Cumulative anticholinergic burden may be a modifiable predictor of frailty among older adults, including those newly diagnosed with dementia. Highlights Patients with newly diagnosed dementia with Lewy bodies (DLB) are more likely to have prescriptions for anticholinergic medications relative to patients newly diagnosed with Alzheimer's disease (AD) and older adults without documented cognitive impairment. In the year prior to a documented dementia diagnosis, 74% of patients with DLB and 66% of patients with AD had evidence of frailty. Anticholinergic medication burden was associated with frailty among all older adults in the study, including those without a dementia diagnosis.
